Polymyxin B-related neurotoxicity : a brief case report
© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ..
Polymyxin B and colistin are considered the last therapeutic option to treat infections caused by highly drug-resistant bacteria. However, their administration may lead to various adverse effects such as nephrotoxicity, neurotoxicity, and allergic reactions. The current case report presents the clinical manifestation of polymyxin B-associated neurotoxicity in a female patient with no chronic illness history. The patient was rescued from under rubble during an earthquake. She was diagnosed with an intra-abdominal infection caused by Acinetobacter baumannii (A. baumannii) After the initiation of the polymyxin B infusion, the patient developed numbness and tingling sensations in her hands, face, and head. On discontinuing polymyxin B and starting colistimethate, the patient's symptoms improved. Therefore, healthcare professionals should be aware of the potential risk factors associated with neurotoxicity in patients receiving polymyxin B. On identifying such symptoms treatment should be discontinued promptly to prevent further neurological damage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
European journal of hospital pharmacy : science and practice - 31(2023), 1 vom: 27. Dez., Seite 66-67 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bayraktar, Izgi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 29.12.2023 Date Revised 24.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/ejhpharm-2023-003786 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357881567 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357881567 | ||
| 003 | DE-627 | ||
| 005 | 20240124231909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ejhpharm-2023-003786 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM357881567 | ||
| 035 | |a (NLM)37286311 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bayraktar, Izgi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polymyxin B-related neurotoxicity |b a brief case report |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2023 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Polymyxin B and colistin are considered the last therapeutic option to treat infections caused by highly drug-resistant bacteria. However, their administration may lead to various adverse effects such as nephrotoxicity, neurotoxicity, and allergic reactions. The current case report presents the clinical manifestation of polymyxin B-associated neurotoxicity in a female patient with no chronic illness history. The patient was rescued from under rubble during an earthquake. She was diagnosed with an intra-abdominal infection caused by Acinetobacter baumannii (A. baumannii) After the initiation of the polymyxin B infusion, the patient developed numbness and tingling sensations in her hands, face, and head. On discontinuing polymyxin B and starting colistimethate, the patient's symptoms improved. Therefore, healthcare professionals should be aware of the potential risk factors associated with neurotoxicity in patients receiving polymyxin B. On identifying such symptoms treatment should be discontinued promptly to prevent further neurological damage | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CLINICAL MEDICINE | |
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Critical Care | |
| 650 | 4 | |a DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS | |
| 650 | 4 | |a MICROBIOLOGY | |
| 650 | 7 | |a Polymyxin B |2 NLM | |
| 650 | 7 | |a J2VZ07J96K |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Halacli, Burcin |e verfasserin |4 aut | |
| 700 | 1 | |a Demirkan, Kutay |e verfasserin |4 aut | |
| 700 | 1 | |a Topeli, Arzu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of hospital pharmacy : science and practice |d 2012 |g 31(2023), 1 vom: 27. Dez., Seite 66-67 |w (DE-627)NLM225772213 |x 2047-9956 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:1 |g day:27 |g month:12 |g pages:66-67 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ejhpharm-2023-003786 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 1 |b 27 |c 12 |h 66-67 | ||